Press Releases
2017 2Q Financial Result Release
|
- Sales declined due to production decrease for regular facility maintenance.
- With construction of plant number 3 to be soon completed, SBL aims to reach its break-even point within the year.
Samsung Biologics Co., Ltd. (CEO: Tae Han Kim) today announced its financial results for the second quarter of 2017. The company posted quarterly sales of KRW 63.2 billion and quarterly operating loss of KRW 8.5 billion.
Samsung Biologics’ sales decreased KRW 44.4 billion compared to the previous quarter due to the decline in production, as the company’s plant 1 and plant 2 went through regular facility maintenance late last year.
The short-term net loss records KRW 22.1 billion, improved by KRW 11 billion from last quarter, due to investment subsidiaries’ earning improved.
Tae Han Kim, CEO of Samsung Biologics, said “Plant 3, which will be the world’s largest in terms of capacity, will be completed by the end of the year and we are actively discussing manufacturing opportunities for plant 3.” He also added that SBL “aims to reach its break-even point this year, as announced during the IPO last year.
?
?
※ Samsung Biologics Financial Result 2Q 2017 (Billion won)
|
2Q 17 |
1Q 17 |
QoQ |
Sales |
63.2 |
107.6 |
?44.4 |
Operating Profit |
?8.5 |
3.4 |
?11.9 |
Net Profit |
?22.1 |
?33.1 |
11 |
?
|
- Sales declined due to production decrease for regular facility maintenance.
- With construction of plant number 3 to be soon completed, SBL aims to reach its break-even point within the year.
Samsung Biologics Co., Ltd. (CEO: Tae Han Kim) today announced its financial results for the second quarter of 2017. The company posted quarterly sales of KRW 63.2 billion and quarterly operating loss of KRW 8.5 billion.
Samsung Biologics’ sales decreased KRW 44.4 billion compared to the previous quarter due to the decline in production, as the company’s plant 1 and plant 2 went through regular facility maintenance late last year.
The short-term net loss records KRW 22.1 billion, improved by KRW 11 billion from last quarter, due to investment subsidiaries’ earning improved.
Tae Han Kim, CEO of Samsung Biologics, said “Plant 3, which will be the world’s largest in terms of capacity, will be completed by the end of the year and we are actively discussing manufacturing opportunities for plant 3.” He also added that SBL “aims to reach its break-even point this year, as announced during the IPO last year.
※ Samsung Biologics Financial Result 2Q 2017 (Billion won)
| 2Q 17 | 1Q 17 | QoQ |
Sales | 63.2 | 107.6 | ∆44.4 |
Operating Profit | ∆8.5 | 3.4 | ∆11.9 |
Net Profit | ∆22.1 | ∆33.1 | 11 |